Abstract
The antimalarials, chloroquine, hydroxychloroquine, and quinacrine, are used primarily for malaria; but they can be beneficial for cutaneous lupus erythematosus (LE), polymorphous light eruption, solar urticaria, and porphyria cutanea tarda. Antimalarials bind to deoxyribonucleic acid (DNA) which prevents DNA and ribonucleic acid (RNA) polymerase reactions and DNA heat inactivation; and they inhibit the LE cell phenomenon, antinuclear antibody reactions, and suppress lymphocyte transformation. By competing with calcium ion, they stabilize membranes and have an anesthetic effect. Their anti-inflammatory potential is due to their inhibition of hydrolytic enzymes, stabilization of lysosomes, interference with prostaglandin synthesis, blocking of chemotaxis, and antagonism of histamine responses. The antimalarials have no sunscreening properties. The most common toxic effects are cutaneous pigmentation, nausea, vomiting, diarrhea, mild ileus, and cycloplegia. There has been a reluctance to use chloroquine and hydroxychloroquine because of the possibility of retinopathy. However, if the "safe" daily dose limit of chloroquine, 2 mg per pound of body weight, and of hydroxychloroquine, 3.5 mg per pound of body weight, is followed, the ...Continue Reading
Citations
Jan 3, 2012·Head and Neck Pathology·Chia-Cheng LiSook-Bin Woo
Dec 10, 2013·Dermatology and Therapy·Philip R Cohen
Nov 18, 2000·Biochimica Et Biophysica Acta·K M Stuhlmeier
Feb 24, 1998·Clinics in Dermatology·L E Rhodes
Mar 4, 2000·Clinics in Dermatology·R WolfV Ruocco
Jun 26, 2001·Mutation Research·J J ClarkeD Jacobson-Kram
Jan 13, 2000·International Journal of Dermatology·S PuavilaiS Ruangkanchanasetr
Aug 11, 2000·Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics·C L KleineggerM W Finkelstein
Mar 15, 2011·DNA and Cell Biology·Suman DasGopinatha Suresh Kumar
Jul 11, 1992·International Journal of Dermatology·J D Hendrix, K E Greer
Mar 1, 1986·Annals of the Rheumatic Diseases·Y MiyachiY Niwa
Nov 14, 2001·American Journal of Clinical Dermatology·O Dereure
Jan 29, 2005·American Journal of Clinical Dermatology·Anna Wozniacka, Daniel P McCauliffe
Dec 17, 2009·Future Oncology·Katerina Gurova
Dec 20, 2012·The American Journal of Dermatopathology·Ana M Molina-RuizLuis Requena
Oct 1, 1989·International Journal of Dermatology·J S LoK J Tomecki
Jul 1, 1983·Pediatric Dermatology·J E Rasmussen
Mar 1, 2013·Circulation Research·Lu LongNicholas W Morrell
May 5, 2020·Open Forum Infectious Diseases·Katelyn A PastickDavid R Boulware
Sep 24, 2004·Physiological Reviews·Andrzej SlominskiJacobo Wortsman
Aug 21, 2014·Lupus·E BezatiJ H Rand
Jun 21, 2013·Journal of Cutaneous Pathology·Bruno Augusto Benevenuto de AndradeOslei Paes de Almeida
Feb 1, 1995·The Australasian Journal of Dermatology·A M DonnellyJ B Rohr
Apr 18, 2002·Lupus·A WozniackaD P McCauliffe
Nov 2, 2006·Basic & Clinical Pharmacology & Toxicology·Leelavinothan Pari, Pidaran Murugan
Feb 1, 2007·Journal of Applied Toxicology : JAT·Akram JamshidzadehHamed Kashafi
Oct 8, 2014·Antimicrobial Agents and Chemotherapy·Vibhati V KulkarnySamuel A Lee
May 18, 2017·The Journal of Dermatological Treatment·Jesper Grønlund HolmSimon Francis Thomsen
Jun 2, 1998·Lupus·T Q NguyenR D Sontheimer
Apr 17, 2004·Internal Medicine Journal·G E M ReevesM Loewenthal
Apr 29, 2000·Lupus·E ToubiT D Golan
Nov 1, 2007·Dermatologic Therapy·Sunil Kalia, Jan P Dutz
May 3, 2006·International Journal of Dermatology·Junko MurataHiroshi Shimizu
Jun 9, 2015·Photodermatology, Photoimmunology & Photomedicine·Assi Levi, Claes D Enk
Jan 13, 2001·Dermatologic Clinics·M J Van Beek, W W Piette
Aug 15, 1998·Dermatologic Clinics·T N DeSilva, D W Kress
Jul 27, 2011·Environmental Toxicology and Pharmacology·J J DattaniK R Desai